PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

A method for treating polyarticular course juvenile idiopathic arthritis (pcJIA) or juvenile psoriatic arthritis (JPsA) in a patient in need thereof, the method comprising administering a therapeutically effective amount of upadacitinib to the patient, wherein:

• if the patient has a body weight in a range from 10 kg to less than 20 kg, administering upadacitinib twice daily as an oral solution at a dose of 3 mg each (3 mg BID);
• if the patient has a body weight in a range from 20 kg to less than 30 kg, administering upadacitinib twice daily as an oral solution at a dose of 4 mg each (4 mg BID);
• and
• if the patient has a body weight of 30 kg or greater, administering upadacitinib twice daily as an oral solution at a dose of 6 mg each (6 mg BID), or administering upadacitinib once daily as a tablet at a dose of 15 mg (15 mg QD).

A method for treating juvenile psoriatic arthritis (JPsA) in a patient in need thereof, the method comprising administering a therapeutically effective amount of upadacitinib to the patient, wherein:

• if the patient has a body weight in a range from 10 kg to less than 20 kg, administering upadacitinib twice daily as an oral solution at a dose of 3 mg each (3 mg BID);
• if the patient has a body weight in a range from 20 kg to less than 30 kg, administering upadacitinib twice daily as an oral solution at a dose of 4 mg each (4 mg BID);
• and
• if the patient has a body weight of 30 kg or greater, administering upadacitinib twice daily as an oral solution at a dose of 6 mg each (6 mg BID), or administering upadacitinib once daily as a tablet at a dose of 15 mg (15 mg QD).